Discovery of an Orally Available, Brain Penetrant BACE1 Inhibitor that Affords Robust CNS Aβ Reduction.
暂无分享,去创建一个
Suresh Babu | William J Greenlee | Xia Chen | Lynn A. Hyde | Corey Strickland | W. Greenlee | A. Stamford | J. Cumming | R. Hodgson | K. Cox | Yusheng Wu | P. Orth | C. Strickland | J. Voigt | Zhaoning Zhu | S. Babu | L. Favreau | T. Guo | M. Kennedy | R. Kuvelkar | E. Parker | D. Tadesse | J. Misiaszek | Xia Chen | L. Hyde | B. Mckittrick | Tao Guo | Brian A McKittrick | Zhaoning Zhu | Jared N Cumming | Reshma Kuvelkar | Matthew E Kennedy | Leonard Favreau | Kathleen Cox | Peter Orth | Eric M Parker | Andrew W Stamford | Johannes H Voigt | Jack D Scott | Sarah W Li | Eric J Gilbert | Lynn A Hyde | Jeffrey Misiaszek | Yusheng Wu | Robert Hodgson | Dawit Tadesse | Rachael Hunter | Chunli Huang | Liwu Hong | Jack D. Scott | E. Gilbert | Chunli Huang | L. Hong | Rachael C. Hunter
[1] W. Richards,et al. Mice deficient in BACE1, the Alzheimer's β-secretase, have normal phenotype and abolished β-amyloid generation , 2001, Nature Neuroscience.
[2] Walter A. Korfmacher,et al. Cassette-accelerated rapid rat screen: a systematic procedure for the dosing and liquid chromatography/atmospheric pressure ionization tandem mass spectrometric analysis of new chemical entities as part of new drug discovery. , 2001, Rapid communications in mass spectrometry : RCM.
[3] Lingyan Wang,et al. Discovery of cyclic acylguanidines as highly potent and selective beta-site amyloid cleaving enzyme (BACE) inhibitors: Part I--inhibitor design and validation. , 2010, Journal of medicinal chemistry.
[4] Ying-zi Xu,et al. Small-molecule BACE1 inhibitors: a patent literature review (2006 – 2011) , 2012, Expert opinion on therapeutic patents.
[5] Lynn A. Hyde,et al. Structure based design of iminohydantoin BACE1 inhibitors: identification of an orally available, centrally active BACE1 inhibitor. , 2012, Bioorganic & medicinal chemistry letters.
[6] I. Kola,et al. BACE knockout mice are healthy despite lacking the primary beta-secretase activity in brain: implications for Alzheimer's disease therapeutics. , 2001, Human molecular genetics.
[7] M. Gallagher,et al. A specific amyloid-β protein assembly in the brain impairs memory , 2006, Nature.
[8] J. Hardy,et al. The Amyloid Hypothesis of Alzheimer ’ s Disease : Progress and Problems on the Road to Therapeutics , 2009 .
[9] J. Ellman,et al. Asymmetric synthesis of beta-amino acid derivatives incorporating a broad range of substitution patterns by enolate additions to tert-butanesulfinyl imines. , 2002, The Journal of organic chemistry.
[10] Gianni Chessari,et al. Application of fragment-based lead generation to the discovery of novel, cyclic amidine beta-secretase inhibitors with nanomolar potency, cellular activity, and high ligand efficiency. , 2007, Journal of medicinal chemistry.
[11] R. Vassar. BACE1: the beta-secretase enzyme in Alzheimer's disease. , 2004, Journal of molecular neuroscience : MN.
[12] P. Verhoest,et al. Strategies to optimize the brain availability of central nervous system drug candidates , 2011, Expert opinion on drug discovery.
[13] S. Stachel. Progress toward the development of a viable BACE‐1 inhibitor , 2009 .
[14] T. Morgan,et al. Diffusible, nonfibrillar ligands derived from Abeta1-42 are potent central nervous system neurotoxins. , 1998, Proceedings of the National Academy of Sciences of the United States of America.
[15] H. Cai,et al. BACE1 is the major β-secretase for generation of Aβ peptides by neurons , 2001, Nature Neuroscience.
[16] B. Strooper,et al. The amyloid cascade hypothesis for Alzheimer's disease: an appraisal for the development of therapeutics , 2011, Nature Reviews Drug Discovery.
[17] Rajiv Chopra,et al. Design and synthesis of 5,5'-disubstituted aminohydantoins as potent and selective human beta-secretase (BACE1) inhibitors. , 2010, Journal of medicinal chemistry.
[18] Michael Czarniecki,et al. Application of fragment-based NMR screening, X-ray crystallography, structure-based design, and focused chemical library design to identify novel microM leads for the development of nM BACE-1 (beta-site APP cleaving enzyme 1) inhibitors. , 2010, Journal of medicinal chemistry.
[19] Paul Zuck,et al. Discovery and X-ray crystallographic analysis of a spiropiperidine iminohydantoin inhibitor of beta-secretase. , 2008, Journal of medicinal chemistry.
[20] Stephen A. Wring,et al. Passive Permeability and P-Glycoprotein-Mediated Efflux Differentiate Central Nervous System (CNS) and Non-CNS Marketed Drugs , 2002, Journal of Pharmacology and Experimental Therapeutics.
[21] Clive McCarthy,et al. Structure based design, synthesis and SAR of cyclic hydroxyethylamine (HEA) BACE-1 inhibitors. , 2011, Bioorganic & medicinal chemistry letters.
[22] P. Saftig,et al. Control of Peripheral Nerve Myelination by the ß-Secretase BACE1 , 2006, Science.
[23] Shaomin Li,et al. Amyloid-β protein dimers isolated directly from Alzheimer's brains impair synaptic plasticity and memory , 2008, Nature Medicine.
[24] P. Wong,et al. Bace1 modulates myelination in the central and peripheral nervous system , 2006, Nature Neuroscience.